Reported 1 day ago
In 2023, unsupported price hikes for five of the top ten drugs significantly contributed to an $815 million increase in U.S. drug spending, according to the Institute for Clinical and Economic Review (ICER). While half of these drugs had price increases supported by clinical evidence, the others, including Johnson & Johnson's Darzalex, did not. This trend highlights ongoing concerns regarding the rising costs of medications, as many prices continue to outpace inflation.
Source: YAHOO